-
AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis
•
The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical industry, opening up diverse application scenarios for AI + healthcare. IVD companies are leveraging AI-empowered products and services to reduce costs and increase efficiency. New algorithms are helping to speed up the integration and application…
-
Zhejiang Dian Diagnostics Partners with Best Covered to Tackle Alzheimer’s Disease
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a China-based medical diagnostics firm, has formed a strategic partnership with Shanghai-based Best Covered, a technology company specializing in Alzheimer’s disease (AD). The collaboration aims to enhance early screening, precise testing, personalized intervention, and digital management of AD. Partnership GoalsThe two companies will…
-
Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District
•
On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was inaugurated in Rongchang District of Chongqing. The center, guided by the local health commission bureau and implemented by China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), aims to optimize and integrate medical laboratory resources within…
-
Zhejiang Dian Diagnostics Partners with SNN/CRHA for Optic Nerve Disease Research
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostic solutions provider, has formed a strategic partnership with the Society for Neuroscience and Neurology, Chinese Research Hospital Association (SNN/CRHA). This collaboration is aimed at conducting comprehensive research into the genetic underpinnings of optic nerve-related diseases, marking a significant step…
-
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
-
Zhejiang Dian Diagnostics Partners with Shanghai Mycology Lab to Advance Fungal Infection Diagnostics
•
SHANGHAI—Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading player in the diagnostics industry, has entered into a strategic partnership with the Shanghai Key Laboratory of Medical Mycology and Molecular Biology. The collaboration aims to delve into multi-center scientific research, product development, and the integration of artificial intelligence (AI) technology…
-
Eisai Forges Partnerships with Chinese Firms to Strengthen Alzheimer’s Disease Market Presence
•
Eisai Co., Ltd, (TYO: 4523) a Japanese pharmaceutical company, has announced separate strategic partnerships with several Chinese healthcare firms, including iKang Healthcare Group, Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), V-Medical, Kindstar Global (HKG: 9960), and Ribose. These collaborations are aimed at tapping into the Alzheimer’s disease (AD) market in…
-
Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has entered into a strategic partnership with Quest Diagnostics, a top global provider of diagnostic information services. The collaboration aims to develop and offer blood-based clinical research services specifically tailored for Alzheimer’s disease (AD). Through this…
-
Zhejiang Dian Diagnostics Partners with Henan Institute to Open Neuroimmunity Research Center
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a medical diagnostics company based in China, has entered into a collaboration with the Henan Institute of Medical and Pharmaceutical Sciences to establish the Engineering Technology Research Center for Accurate Diagnosis and Treatment of Neuroimmunity. The new research institute has been officially inaugurated…
-
Zhejiang Dian Diagnostics Partners with Hangzhou Medical College to Establish Education Base
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent player in the medical diagnostics space, has entered into a strategic partnership with Hangzhou Medical College to establish a graduate education base focused on biology and medicine. This collaboration aims to create a conducive environment for the next generation of medical…
-
Zhejiang Dian Diagnostics Partners with Haihe Laboratory to Advance Hematology Diagnostics
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a company based in China, has entered into a strategic partnership with the Haihe Laboratory of Cell Ecosystem under the China Academy of Medical Sciences. The collaboration aims to drive research translation, standardize disease diagnosis and treatment, advance digital healthcare, and enhance discipline…
-
Zhejiang Dian Diagnostics Partners with Gulf Medical University for Middle East Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a Chinese diagnostics company, has entered into a cooperation intention agreement with the United Arab Emirates’ Gulf Medical University. The collaboration aims to encompass talent exchange, channel construction, scientific research, and commercial translational research, among other areas. Financial details of the agreement have…
-
Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the first half of 2023, recording revenues of RMB 6.842 billion (USD 938.7 million), marking a year-on-year (YOY) decrease of 36.37%. Net profits were reported at RMB 453 million, reflecting a significant YOY decrease of 75.89%.…
-
Zhejiang Dian Diagnostics Partners with Northeast Infectious Diseases Alliance to Enhance Surveillance
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics specialist based in China, has entered into a strategic partnership with the Northeast Infectious Diseases Alliance. The collaboration aims to establish a standardized three-level monitoring system for infectious diseases, enhancing the capabilities of central monitoring hospitals and bolstering the region’s…
-
Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion
•
Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China, has entered into a strategic partnership with Meituan, the country’s leading delivery giant, to explore new digital and intelligent medical and healthcare service models. The collaboration aims to leverage the strengths of both companies to…
-
Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production
•
Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed amount of money in a Series B+ financing round. The round was led by GF Xinde Investment and a private equity fund initiated by Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244). The proceeds will be…
-
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
•
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244) and Tigermed (SHE: 300347, HKG: 3347), has struck a partnership with Belgium-headquartered Cerba Healthcare’s subsidiary Cerba Research. The two companies will set up a JV in Wuxi, Jiangsu Province, China, marking a significant expansion of…
-
Zhejiang Dian Diagnostics Partners with Chengdu Eastern New Area for IVD Hub
•
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has announced a strategic partnership with Chengdu Eastern New Area, focusing on medical diagnosis services, diagnostics development, and other related areas. The collaboration includes plans to establish a domestic in vitro diagnostics (IVD) manufacturing center in the region. Financial details of the…
